Annual report pursuant to Section 13 and 15(d)

Business (Details Narrative)

Business (Details Narrative) (USD $)
Sep. 21, 2011
Jun. 30, 2011
Dec. 31, 2010
Dec. 31, 2009
Accounting Policies [Abstract]        
Acquisition of outstanding common stock of BioZone Labs   $ 100    
Exchanged outstanding stock into shares of common stock   19,266,055    
Outstanding membership interests of Equalan and Equachem   100.00%    
Exchanged membership interest of Equalan for common stock   1,027,523    
Exchanged membership interest of Equachem for common stock   385,321    
Outstanding membership interests of BetaZone   45.00%    
Exchanged membership interest of BetaZone for common stock   321,101    
Total number of shares from acquisition   21,000,000    
Fair value of acquisition   2,000,000    
Common stock issued for delay in filing Form S-1 13,914      
Price per share of common stock issued for delay $ 0.50      
Acquired brands 110,000      
Acquired customer relationships $ 172,800      
Number of shares outstanding, original amount     21,000,000 44,749,999
Number of shares outstanding, reduced amount       21,000,000